文献速递糖尿病

糖尿病病程与晚期并发症:下肢血运重建与冠状动脉血运重建患者的比较

Diabetes duration and advanced diabetes-related complications in lower-extremity versus coronary revascularization.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-25

本研究为横断面分析,纳入5808例接受下肢或冠状动脉血运重建的糖尿病患者。下肢血运重建组糖尿病病程更长,晚期并发症患病率更高,且校正病程后仍更高;而两组糖化血红蛋白无显著差异。

要点

  • 下肢血运重建患者糖尿病病程长于冠状动脉血运重建患者。
  • 下肢血运重建组晚期糖尿病并发症患病率更高。
  • 校正糖尿病病程后,下肢组并发症患病率仍更高。

核心结论

  • 接受下肢血运重建的糖尿病患者糖尿病病程更长。
  • 该类患者晚期糖尿病并发症患病率更高,且校正病程后仍更高。

研究设计与样本

  • 横断面研究,分析前瞻性多中心注册的5808例接受下肢或冠状动脉血运重建的糖尿病患者。

主要发现

  • 下肢血运重建组糖尿病病程更长且晚期并发症患病率更高。
  • 两组血运重建时糖化血红蛋白水平无显著差异。
  • 校正糖尿病病程后,下肢组晚期并发症患病率仍更高。

关键数值与推荐

  • 下肢组相对冠状动脉组的校正患病率比为:增殖性视网膜病变1.57(95%CI 1.41-1.75,P<0.001)。
  • 保护性感觉丧失的校正患病率比为2.39(95%CI 1.82-3.13,P<0.001)。
  • 透析依赖的肾衰竭的校正患病率比为2.12(95%CI 1.82-3.13,P<0.001)。

临床怎么用

  • 对接受下肢血运重建的糖尿病患者,应更重视长病程及晚期并发症的筛查与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Diabetes-related burden, including longer diabetes duration and advanced complications, substantially influences management strategies and healthcare utilization among patients with diabetes. It remains unclear whether the diabetes-related burden is comparable between patients with lower extremity artery disease (LEAD) and those with coronary artery disease (CAD), which are commonly grouped as manifestations of cardiovascular disease. OBJECTIVE: This study aimed to compare diabetes-related burden between patients with diabetes undergoing revascularization for LEAD and those undergoing revascularization for CAD. METHODS: This cross-sectional study analyzed 5,808 patients with diabetes undergoing revascularization for LEAD or CAD, who were registered in a prospective multicenter study. Diabetes duration, glycated hemoglobin levels, and the presence of advanced diabetes-related complications were assessed at the time of index revascularization and compared cross-sectionally between the LEAD and CAD groups. RESULTS: The LEAD group exhibited a longer diabetes duration and a higher prevalence of advanced complications, whereas glycated hemoglobin levels at revascularization did not significantly differ between the groups. The prevalence of advanced complications remained higher in the LEAD group after adjustment for diabetes duration. The adjusted prevalence ratios of LEAD relative to CAD were 1.57 (95% confidence interval, 1.41-1.75, P < 0.001) for proliferative retinopathy, 2.39 (1.82-3.13, P < 0.001) for loss of protective sensation, and 2.12 (1.82-3.13, P <0.001) for dialysis-dependent renal failure, respectively. CONCLUSIONS: Patients undergoing revascularization for LEAD exhibited a longer diabetes duration than those undergoing revascularization for CAD. They also had a higher prevalence of advanced diabetes-related complications, even after adjustment for diabetes duration.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Takahara M, Soga Y, Iida O, et al. Diabetes duration and advanced diabetes-related complications in lower-extremity versus coronary revascularization. J Clin Endocrinol Metab. 2026. PMID: 42788620. doi:10.1210/clinem/dgag387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。